Status: Recruiting
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.
Participants needed: 300
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: NewAmsterdam PharmaUpdated: Mar 10, 2026Locations: 20
Eligibility criteria
fasting serum LDL-C ≥ 70 mg/dL (≥1.81 mmol/L) [+4]
Have current or any previous history of New York Heart Association class III or... [+5]